RxDoctor Payments Data

Tarek Shahbandar, MD

Pain Medicine · Merrillville, INNPI 1922007749

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,806 of the $8,383 with a category attached, or 69.3%. 35 manufacturers reported payments, led by Spinal Simplicity, LLC at 24.1% of the total. Reporting peaked in 2021 at $2,958 and has fallen 89.6% since, to $308 in 2025.

$8,383in general payments, 2019–2025

Across 263 payments — averaging $31.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Simplicity, LLC$2K
  • Abbott$1K
  • Medtronic$925
  • Aurora Spine, Inc.$651
  • Boston Scientific$561
  • Collegium Pharmaceutical, Inc.$456
  • plus $3K from 29 others

What the payments were for

  • Travel & lodging$96311%
  • Food & beverage$5,80669%
  • Education$1,61319%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,383 in reported general payments places this provider in the 75th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$172,494
Medicare patients
389
Services billed
1,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen24$113,456
OxycontinOxycodone Hcl57$42,022
Xtampza ErOxycodone Myristate28$28,784
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen615$18,391
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen763$17,023
BelbucaBuprenorphine Hcl28$14,245
Fentanyl70$10,789
Lidocaine111$9,162
MovantikNaloxegol Oxalate21$8,497
Buprenorphine44$7,735
Pregabalin250$6,091
Gabapentin343$3,755
Morphine Sulfate ErMorphine Sulfate100$2,863
Naloxone Hcl47$2,645
Methadone Hcl60$2,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$456$43,02956 claims
Redhill Biopharma Inc.Movantik$41$8,49721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →